A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas

Bergman, Reuven; Azzam, Halim; Sprecher, Eli; Manov, Lena; Munichor, Mariana; Friedman‐Birnbaum, Rachel; Ben-Itzhak, Offer

doi:10.1016/s0190-9622(00)90226-3

Cited by 41 publications

(19 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unfortunately, it differentiate between benign and malignant nevocellular forms, and is rarely expressed in melanoma metastases or in desmoplastic and spindle‐cell melanomas. As the probability of melanoma decreases (even more that that of nevocellular or Spitz nevus) with increasing tumour depth, it appears that MART‐1/melan‐A positivity reflects the greater immunogenicity of these melanocytic nevi, with respect to melanoma, and thus their greater capacity for eliciting a defensive response 23 . From a prognostic point of view, it would be interesting to see how the expression of this marker correlates with the characteristics of the reactive lymphocytic infiltrate (i.e.…”

Section: Immunohistochemical Markersmentioning

confidence: 99%

Prognostic signs in melanoma: state of the art

Lomuto

Calabrese

Giuliani

2004

Acad Dermatol Venereol

View full text Add to dashboard Cite

Prognoses for melanoma patients are currently based on statistically confirmed parameters, above all the Breslow thickness and number of lymph node and/or distant metastases. However, metastases can develop even with "thin" melanomas (< 0.7 mm), while survival has been recorded in patients with tumours classified as "thick" (> 4 mm). This review of the literature examines the most recent advances in prognostic markers for melanoma (serological, immunohistochemical, histological, genetic and surgical). These markers offer interesting possibilities in terms of diagnostic certainty, identification of early growth phases and estimation of the tumour's potential for progression and metastasis. It is reasonable to assume that their combined use can provide useful information for formulating prognoses that are not only statistically valid but also individualized.

show abstract

Section: Immunohistochemical Markersmentioning

confidence: 99%

Prognostic signs in melanoma: state of the art

Lomuto

Calabrese

Giuliani

2004

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…1 Currently, there are no immunohistochemical studies or molecular biology techniques that can be used to make an entirely safe diagnosis of Spitz nevus or melanoma in problematic cases, although many attempts have been made to do so. [2][3][4][5][6][7][8][9] Histopathological study continues to be the gold standard for Spitz nevus diagnosis, although in some rare cases, even expert dermatopathologists do not guarantee safe diagnosis. 10 In the present work, 349 cases of unequivocal Spitz nevi were studied and their clinical and histopathological characteristics reviewed to establish the most reliable histopathological criteria to diagnose Spitz nevus and their possible relationship with clinical parameters.…”

Section: Introductionmentioning

confidence: 99%

Spitz Nevus: A Clinicopathological Study of 349 Cases

Requena

Requena²,

Kutzner³

et al. 2009

The American Journal of Dermatopathology

160

143

View full text Add to dashboard Cite

Spitz nevus is an infrequent, usually acquired melanocytic nevus composed of epithelioid and/or spindle melanocytes that can occasionally be confused with melanoma. Currently, there are no immunohistochemical markers or molecular biology techniques that can be used to make an entirely safe diagnosis of Spitz nevus or melanoma in problematic cases. A retrospective study has been carried out that included all the cases diagnosed as Spitz nevus from our files. Follow-up information of the patients was unavailable. Three hundred forty-nine cases of unequivocal Spitz nevi were included, and their clinical and histopathological parameters were reviewed. One hundred and forty patients (40%) were 15 years old or younger, with a male to female ratio of 1:1. In patients older than 15 years, there was an evident predominance of women, with a male to female ratio of around 1:3. Spitz nevus was most commonly located on the lower extremities, followed by the trunk in both children and adults. Despite the fact that the head and neck were the third most common location in children, it was a much more frequent location in children than in adults. The constitution by epithelioid and/or spindled cells was the only histopathological finding present in 100% of cases. The other pathological findings studied were, from more to less frequent: maturation (72%), inflammatory infiltrate (70%), epidermal hyperplasia (66%), melanin (50%), telangiectasias (40%), Kamino bodies (34%), desmoplastic stroma (26%), mitosis (23%), pagetoid extension (13%), and hyalinization of the stroma (8%). Hyalinization was the only histopathological parameter that was statistically more frequent in adults than in children.

show abstract

“…5,7,8,19,20 Within a short period of time after their introduction, A103/M2-7C10 and T311 have become popular markers for diagnostic use in pathology, especially for the workup of amelanotic metastatic tumors and detection of micrometastases in sentinel lymph node of patients with primary cutaneous melanoma. [1][2][3]6,[10][11][12][13][14]17,28 The mAb D5 may also be helpful in selected settings, but its staining profile is less restricted to melanocytes than T311 and A103/M2-7C10 5,22,24,25,28 because the antibody was generated to a protein derived from the consensus region shared by various isoforms of microphthalmia transcription factor (MITF). Only one isoform (MITF-M) is melanocyte-specific.…”

mentioning

confidence: 99%

Immunohistochemical Analysis of Novel Monoclonal Antibody PNL2 and Comparison With Other Melanocyte Differentiation Markers

Busam

Kucukgol²,

Satô³

et al. 2005

The American Journal of Surgical Pathology

View full text Add to dashboard Cite

PNL2 is a novel monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocyte and tumors derived thereof. In the present study, we analyzed the immunoreactivity of this mAb in various normal tissues, melanocytic nevi, primary and metastatic melanoma, nonmelanocytic tumors, including histologic mimickers of melanoma as well as angiomyolipoma, and multiple cell lines derived from different tumors types. We used several tissue microarray panels as well as selected conventional sections from tissue blocks. For metastatic melanoma, immunoreactivity for PNL2 was compared with A103 (Melan-A/MART-1), T311 (tyrosinase), HMB45 (gp100), and D5 (MITF). Positive staining with PNL2 was found in normal melanocytes and neutrophils, but no other normal cell type. Among melanocytic lesions, both benign nevi as well as primary malignant melanomas, especially epithelioid variants thereof, were commonly immunopositive. Only 1 of 13 desmoplastic melanomas reacted with PNL2. PNL2 showed high sensitivity for metastatic melanoma (87%). In comparison, 82% of metastatic melanomas were positive for A103, 76% for HMB45, 92% for T311, and 84% for D5. The combined use of all five reagents minimized the number of immunonegative cases. None of the selected nonmelanocytic tumors (carcinomas or soft tissue neoplasms) was positive for PNL2 in this series except for angiomyolipomas and chronic myeloid leukemias and 1 single case of a malignant peripheral nerve sheath tumor with heterologous differentiation (malignant Triton tumor). Despite its reactivity with neutrophils, PNL2 appears to be a valuable supplementary reagent for the diagnosis of melanocytic tumors.

show abstract

A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas

Cited by 41 publications

References 14 publications

Prognostic signs in melanoma: state of the art

Prognostic signs in melanoma: state of the art

Spitz Nevus: A Clinicopathological Study of 349 Cases

Immunohistochemical Analysis of Novel Monoclonal Antibody PNL2 and Comparison With Other Melanocyte Differentiation Markers

Contact Info

Product

Resources

About